Interestingly, when comparing DNAM-1+ with DNAM-1− NK cells and their tumor rejection capacity and in vitro killing, DNAM-1+ NK cells showed superior rejection and tumor killing capacity of B16 melanoma cells and RMA-S lymphoma cells41, 42. This evidence concerns the gene CD226 and lymphoma.